Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zymeworks's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zymeworks's regulatory disclosures and financial reporting.
Zymeworks Inc. announces its 2025 annual meeting of stockholders. The virtual meeting will be held on December 30, 2025 at 9:00 a.m. Pacific Time via live audio webcast at meetnow.global/MZKC5MK. Stockholders of record at the close of business on November 3, 2025 may attend and vote.
The agenda includes three items: elect three directors, an advisory vote on executive compensation, and ratification of the appointment of the auditors. A quorum requires at least 33 1/3% of the voting power present or represented by proxy. Broker non-votes and abstentions count toward quorum but are not votes cast on proposals.
As of the record date, 74,835,565 shares of common stock were outstanding. In addition, six registered holders of exchangeable shares held 553,184 exchangeable shares eligible to exercise voting rights at the meeting. Beneficial holders generally must obtain a legal proxy to vote virtually. The company has engaged Kingsdale Advisors to assist with proxy solicitation.
The board remains majority independent, with Kenneth Galbraith serving as Chair, Chief Executive Officer and President, and Susan Mahony as Lead Independent Director. Three directors resigned effective November 6, 2025, and committee memberships were updated accordingly.
Zymeworks Inc. filed its Q3 2025 report, showing higher collaboration revenue and a narrower quarterly loss. Revenue from research and development collaborations was $27,614 for the quarter (vs. $16,000 a year ago), aided by partner milestones. Net loss was $19,602, translating to basic and diluted loss per share of $0.26.
For the nine months, collaboration revenue reached $103,450 (vs. $45,273), supported by payments from J&J ($25,000 Phase 3 start), BeOne ($20,000 milestone plus $18,334 deferred revenue recognized), BMS ($7,500 option), GSK ($14,000), and Daiichi Sankyo ($3,100). Operating expenses were $49,724 in Q3, with R&D of $35,578 and G&A of $14,146. Cash and cash equivalents were $64,834, with marketable securities of $234,526, and total assets of $397,269. The company repurchased 1,028,333 shares in Q3 for $15,691 and completed the net exercise of 5,086,480 pre‑funded warrants in June. Shares outstanding were 74,836,534 as of November 4, 2025.
Zymeworks Inc. (ZYME) furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1 to a Form 8-K.
The information under Items 2.02 and 7.01 and Exhibit 99.1 is furnished and is not deemed “filed” for Section 18 of the Exchange Act or incorporated by reference, except as specifically stated. Zymeworks also notes it shares material updates via SEC filings, its websites, and official social media channels.
Zymeworks Inc. has decided to voluntarily discontinue clinical development of ZW171, a T cell engager targeting gynecological, thoracic, and digestive system cancers. The decision follows completion of the planned dose-escalation cohorts in a Phase 1 trial in patients with ovarian cancer and non-small cell lung cancer, where a maximum tolerated dose was established. After reviewing these results, the company concluded that further dose evaluation in the current trial was unlikely to support a benefit-risk profile consistent with the desired monotherapy target product profile. The decision was announced via press release furnished as an exhibit.
Zymeworks Inc. (ZYME) Schedule 13G/A reports that Redmile Group, LLC and its principal Jeremy C. Green each have shared voting and dispositive power over 4,150,627 shares of Zymeworks common stock, representing 5.6% of the class based on 74,844,505 shares outstanding as of June 27, 2025. One Redmile vehicle, Redmile Biopharma Investments III, L.P., holds 3,470,727 shares ( 4.6%). The filers state the shares are held by Redmile-managed private investment vehicles, that Redmile and Mr. Green may be deemed beneficial owners solely as manager/principal, and they disclaim beneficial ownership except to the extent of any pecuniary interest. The filing certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control.
Gregory Austin Ciongoli, a director of Zymeworks Inc. (ZYME), reported acquisitions of company securities in August 2025. The Form 4 shows he acquired 415,000 shares of common stock on 08/12/2025 at a price of $12.02, bringing his reported direct beneficial ownership to 488,500 shares.
The filing also discloses an indirect holding of 5,000 shares held by 4 Arrows Holdings, LLC, for which he is manager, and a grant of 62,000 stock options on 08/11/2025 with an exercise price of $12.44. The options vest in 36 equal monthly installments beginning one month after the grant date and show an expiration date of 08/10/2035. The Form 4 was signed by an attorney-in-fact on 08/12/2025.
Robert E. Landry, a director of Zymeworks Inc. (ZYME), was granted stock options on 08/11/2025. The award consists of options to purchase 62,000 shares of common stock at an exercise price of $12.44 per share, with an expiration date of 08/10/2035. The options vest in 36 equal monthly installments beginning one month after the grant date. Following the reported transaction, Mr. Landry directly beneficially owns 62,000 option units.
Zymeworks Inc. director Robert E. Landry filed an initial Form 3 reporting that he does not beneficially own any shares or derivative securities of the company. The filing identifies Mr. Landry as a director and indicates the submission covers a single reporting person. No transactions, grants, or indirect ownership arrangements are disclosed in the form.
Zymeworks director Gregory Austin Ciongoli filed an initial Form 3 reporting beneficial ownership in the issuer. He directly owns 73,500 shares of common stock and, as manager of 4 Arrows Holdings, LLC, exercises sole voting and dispositive power over an additional 5,000 shares while disclaiming beneficial ownership except for his pecuniary interest. The Form 3 lists the event date as 08/10/2025 and includes a signature by an attorney-in-fact dated 08/12/2025.
Zymeworks Inc. appointed Gregory A. Ciongoli and Robert E. Landry to its board effective August 10, 2025; Mr. Ciongoli was named a Class II director with a term expiring at the 2026 annual meeting and Mr. Landry was named a Class I director with a term expiring at the 2025 annual meeting. Both were added to the Audit Committee and will receive the companys standard non-employee director compensation, including an initial stock option grant to purchase 62,000 shares each.
Separately, the company entered into a private placement under which Mr. Ciongoli agreed to buy 415,000 shares at $12.02 per share for an aggregate purchase price of $4,988,300; closing is expected on or about August 12, 2025 and proceeds are intended for working capital and general corporate purposes. Troy M. Cox resigned from the board effective August 9, 2025, and the company stated the resignation was not due to any disagreement with the company.